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Inflammation is associated with the development of diseases characterized by altered nutrient metabolism.
Although an acute inflammatory response is host-protective and normally self-limited, chronic low-grade
inflammation associated with metabolic diseases is sustained and detrimental. The resolution of inflamma-
tion involves the termination of neutrophil recruitment, counterregulation of proinflammatory mediators,
stimulation of macrophage-mediated clearance, and tissue remodeling. Specialized proresolving lipid medi-
ators (SPMs)–resolvins, protectins, and maresins–are novel autacoids that resolve inflammation, protect
organs, and stimulate tissue regeneration. Here, we review evidence that the failure of resolution programs
contributes to metabolic diseases and that SPMs may play pivotal roles in their resolution.Initiation and Resolution of Acute Inflammation:
Identification of the Proresolving Mediators
Acute inflammatory responses are protective for the host, yet,
when uncontrolled or inappropriately activated, acute inflamma-
tion can lead to persistent chronic inflammation that is unre-
solved and can promote organ fibrosis and dysfunction
(Figure 1A) (Majno and Joris, 2004). Although chronic inflamma-
tion is classically associated with arthritis and periodontitis (Gil-
roy, 2010; Karp, 2010; Ward, 2010), there is increasing evidence
that uncontrolled inflammation is also associated with many
other chronic diseases, such as asthma and neurological degen-
erative disorders, as well as metabolic diseases, including dia-
betes, obesity, and cardiovascular disease (reviewed in Nathan
and Ding, 2010; Tabas and Glass, 2013). An acute inflammatory
response is, by definition, divided into an initiation phase and a
resolution phase. The initiation phase is accompanied by the
cardinal signs of inflammation known to ancient civilizations as
heat, swelling, and pain (Majno and Joris, 2004) with eventual
losses of function that are controlled, for the most part, by local
chemical autacoids (Houck, 1979). A majority of these chemical
messengers are in the form of peptides (cytokines and chemo-
kines), proteins, and lipid-derived mediators (prostaglandins
and leukotrienes) that form chemical gradients that regulate
leukocyte trafficking via chemotaxis and diapedesis from the
blood stream into the injured tissue. The phagocytes contain
invading microbes and clear tissue debris or remove environ-
mental toxins that appear in tissues as a result of barrier disrup-
tion. The repertoire of edema, polymorphonuclear neutrophil
(PMN) infiltration, and monocyte-macrophage accumulation en-
sues as a characteristic sequence of events during the initiation
of the acute inflammatory response (Figure 1A) (Cassatella,
2003; Gilroy, 2010; Karp, 2010; Ward, 2010). Without an appro-
priate termination and clearance of phagocytes, the continued
presence of activated leukocytes within tissues is associated
with collateral tissue damage, amplification, and the persistenceof tissue inflammation. Hence, controlling PMN infiltration,
cessation, and removal from tissues as well as macrophage
accumulation, activation, and removal could attenuate nonre-
solving chronic tissue inflammation.
Many initiation-phase proinflammatory mediators are well
known (i.e., prostaglandins and proinflammatory cytokines),
and popular anti-inflammatory treatments are directed toward
either blocking or antagonizing these mediators in a quest to
control unwanted excessive inflammation (Samuelsson et al.,
1987; Flower, 2006; Dinarello et al., 2012). What controls or limits
the number of leukocytes that congregate within inflammatory
exudates? How are signaling events organized toward resolving
the acute inflammatory response (i.e., the removal of apoptotic
PMNs and cellular debris), promoting the return to homeostasis,
which is the ideal outcome of an inflammatory challenge (Serhan
et al., 2000; Levy et al., 2001; Serhan, 2004)? The resolution of
inflammation and return to homeostasis was widely believed to
occur via the dissipation of initiating chemotactic signals in the
acute inflammatory response (Majno and Joris, 2004). This
dissipation can arise partly because of extensive negative feed-
back regulation of Toll-like receptor (TLR) signaling via the induc-
tion of IkB-a and A20 as well as transcriptional repressors,
including activating transcription factor 3, for example (Olefsky
and Glass, 2010). In addition, anti-inflammatory cytokines such
as IL-10 also blunt inflammatory gene transcription. However,
in addition to a decrescendo of proinflammatory mediators,
ample evidence now shows that the resolution of contained
inflammatory exudates is an actively programmed biochemical
process regulated by the temporal biosynthesis of novel chemi-
cal mediators during the resolution phase. As described below,
these proresolving mediators not only counterregulate inflam-
matory gene transcription but also directly block and limit exces-
sive PMN migration and stimulate distinct cellular processes,
such as macrophage uptake of apoptotic PMNs, microbes,
and cellular debris that are required for tissue homeostasis toCell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc. 21
Figure 1. Specialized Proresolving Lipid
Mediator Biosynthesis during Resolution
of Inflammation
(A) Complete resolution is the ideal outcome of
inflammation, although, if not properly regulated, it
can lead to chronic inflammation, fibrosis, and loss
of function. Inflammation and its resolution in-
volves a temporal series of leukocyte trafficking
events coupled with lipid mediator class switch-
ing, in which proinflammatory lipid mediators
signal the generation of proresolving lipid media-
tors.
(B) A depiction of classic and novel lipid mediator
families generated from essential omega-6 (n-6)
and omega-3 (n-3) fatty acids, arachidonic acid
(AA), eicosapentaenoic acid (EPA), and docosa-
hexaenoic acid (DHA).
(C) Abbreviated biosynthetic pathways and
structures of resolvins, protectins, and maresins
generated enzymatically from DHA. Their com-
plete stereochemical structures are established;
see Lipid Mediator Class Switching during
Inflammation and Its Resolution: Alpha Signals
Omega for details. LOX, lipoxygenase; RvD1,
resolvin D1; PD1, protectin D1; MaR1, maresin 1.
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et al., 2002; Serhan and Savill, 2005). These findings swiftly
raised the possibility that the failed resolution of an inflammatory
challenge could potentially lead to recurring bouts of persistent
tissue inflammation and diseases associated with chronic
inflammation as well as the notion that the resolution phase is
exciting new terrain for targeted innovative therapeutics (Serhan
et al., 2007; Buckley et al., 2013).
Resolution is defined at the tissue level with the cessation of
leukocyte infiltration in response to chemotactic signals, timely
apoptosis of PMNs, and the accompanied active clearance of
apoptotic cells and debris by macrophages (Serhan, 2004;
Ward, 2010). Using a systems approach with liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS)-based analysis
of self-limited inflammatoryexudates (ones that resolve tohomeo-
stasis on their own) formed in vivo in animal models as well as in
isolated human cells, the Serhan laboratory, over several years,22 Cell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc.identified a novel genus of bioactivemedi-
ators that comprise four families of distinct
structures, namely lipoxins, resolvins, pro-
tectins, and maresins, all of which are
biosynthesizedwithin the resolutionphase
of acute inflammation (Levy et al., 2001;
Serhan et al., 2000, 2002; Hong et al.,
2003). These new local mediators acti-
vate previously unappreciated proresolv-
ing mechanisms, and their identification
demonstrated that the resolution phase
of acute inflammation is a biosynthetically
active process (Serhan and Savill, 2005).
Lipid Mediator Class Switching
during Inflammation and Its
Resolution: Alpha Signals Omega
The initiation of acute inflammation is
controlled by a number of autacoids,including lipid mediators such as the eicosanoids, prostaglan-
dins (PGs), and leukotrienes, which are formed from arachidonic
acid (AA; omega 6) and play key roles in regulating blood flow,
endothelial permeability, and PMN diapedesis (Samuelsson
et al., 1987). Transendothelial migration and chemotaxis of
PMNs toward injured tissue and/or pathogens is governed in
part by leukotriene B4 (LTB4) and chemokines (Figures 1A and
1B). Unexpectedly, we found that there is a temporal switch in
lipid mediators from the initiation phase to resolution; that is,
different lipid mediators are generated at different times during
the evolution of the inflammatory response, and these mediators
coincide with distinct cellular traffic and events. Although
maximal levels of LTB4 occur as PMN infiltrate tissues, other
eicosanoids, including the proinflammatory cyclooxygenase
products PGE2 and PGD2, initiate a lipid mediator class
switch—a mediator circuit in exudates that activates leukocyte
translational regulation of the enzymes required for producing
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PGD2 stimulate the biosynthesis of lipoxin A4 (LXA4), which
appears in exudates at the time point at which PMN levels
decline. Indeed, LXA4 serves as an endogenous ‘‘stop’’ signal
that decreases PMN infiltration. Thus, signals that mediate the
resolution of a contained acute inflammatory response are tightly
linked to mediators of the initiation phase; i.e., the beginning
programs the end of inflammation (Serhan and Savill, 2005).
Specialized proresolving lipid mediators (SPMs) can be gener-
ated via transcellular biosynthesis, and their appearance in-
creases when macrophages are actively clearing apoptotic
PMNs (Dalli and Serhan, 2012). Indeed, macrophage phagocy-
tosis of apoptotic cells also leads to the biosynthesis of
proresolving lipid mediators, which act in an autocrine manner
to facilitate phagocytosis. This mechanism of biosynthesis,
coupled with the potent regulation of inflammatory gene
transcription, is similar to that of other ‘‘find me’’ and ‘‘eat me’’
signals (e.g., adenosine, ATP, andCX3CL1) generated by phago-
cytes that play a key role in the immunologically silent process of
apoptotic cell clearance (Han andRavichandran, 2011; Ko¨ro¨ske´-
nyi et al., 2011).
To emphasize the specificity of their actions and specialized
roles in inflammation, we coined the term ‘‘specialized proresolv-
ing lipid mediators.’’ This genus includes several families of
chemically and functionally distinct mediators, namely the lipox-
ins, resolvins, protectins, andmaresins, because they blunt PMN
infiltration, decrease proinflammatory mediator production (both
lipid mediators and cytokines), and stimulate macrophage-
dependent uptake of apoptotic PMNs as well as bacterial clear-
ance (Serhan and Savill, 2005; Chiang et al., 2012). Notably,
SPMs also regulate PMN apoptosis (see below) and stimulate
chemokine scavenging (e.g., CCL3 and CCL5) during resolution
via the upregulation of CCR5 expression on apoptotic PMNs
and T cells (Ariel et al., 2006). This mechanism facilitates the
clearance of these chemokines from sites of inflammation, given
that the apoptotic cells and bound chemokines are cleared by
macrophages and that CCR5-dependent signaling is lost in
apoptotic cells (Ariel et al., 2006). Systematic identification of
these endogenousmediators indicated that they are novel struc-
tures and that the precursors for resolvins, protectins, andmare-
sins are the omega-3 essential fatty acids eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA), whereas the lipoxins are
generated from the omega-6 fatty acid AA (Figure 1B). It should
be noted that, in addition to the SPMs described here, other res-
olution agonists, including glucocorticoid-induced annexin A1,
are also important players (Perretti and D’Acquisto, 2009).
E-series resolvins (e.g., RvE1, RvE2, and RvE3) are produced
from EPA, and DHA is a precursor of three novel families of
distinct SPMs that include the D-series resolvins, protectins
(including PD1 or neuroprotectin [N]PD1 when formed in neural
tissues), and maresins (Serhan, 2007; Isobe et al., 2012)
(Figure 1C). There are also temporal relationships between
different SPM families and individual mediators produced in
response to pathogens (e.g., viral versus bacterial) that trigger
the production of select host SPMs (Chiang et al., 2012; Koltsida
et al., 2013; Morita et al., 2013). This suggests that, even within
the SPM genus, there are distinct roles for individual SPMs
and that the complexities of their biosynthesis are just beginning
to be appreciated.It is extensively documented that, in certain clinical settings,
omega-3 essential fatty acids (EPA and DHA) regulate both
innate and acquired immune responses (reviewed in De
Caterina, 2011; Calder, 2013). SPMs are generated in humans
taking omega-3 dietary supplements, and SPM levels are
increased above those produced normally in transgenicmice ex-
pressing an omega-3 fatty acid desaturase (fat-1) (Hudert et al.,
2006; Mas et al., 2012). The identification of the SPM structures,
mapping of their biosynthetic pathways, and stereochemical as-
signments for each of the SPMs, coupled with the elucidation of
their potent actions with human cells and in numerous animal
models of inflammation, collectively suggests that SPM forma-
tionmay underlie some of the beneficial effects attributed to their
precursors EPA and DHA (Serhan and Chiang, 2013). Like other
small molecules, SPMs evoke stereospecific bioactions medi-
ated in the nanomolar range by their binding to specific G pro-
tein-coupled receptors (GPCRs; Figure 2). Systematic receptor
screening approaches along with radioligand-specific binding
and results from competition studies identified GPCRs activated
by SPMs, namely, ChemR23/ERV for RvE1 and RvE2 and ALX/
FPR2 and GPR32/DRV for LXA4 and RvD1 (Serhan and Chiang,
2013). Interestingly, GPR32 is also activated by RvD5 and RvD3
(Dalli et al., 2013), whereas other proresolving mediators,
including annexin A1, activate ALX/FPR2 (Norling and Perretti,
2013). NPD1/PD1 displays specific binding to PMNs and human
epithelial cells where neither RvE1 nor LXA4 competes for PD1-
specific binding, indicating that PD1 actions are most likely
mediated by separate receptors. Binding studies using specific
receptor expression constructs corroborate their potent actions
on isolated cell types and in vivo, Kd values being in the picomo-
lar-nanomolar range (Serhan and Chiang, 2013).
RvE1 and RvE2 are also endogenous receptor antagonists for
the LTB4 receptor BLT-1, which most likely explains their ability
to potently regulate PMN trafficking to sites of inflammation. The
endogenous role of these specific GPCRs in transmitting SPM
signals has now been elucidated in vivo in mice with transgenic
overexpression of ChemR23 and ALX/FPR2 as well asmice defi-
cient in Fpr2 (the murine isoform of ALX/FPR2), and this has pro-
vided insights into the biological role of proresolving receptors
(Serhan and Chiang, 2013). It should be noted that the substrate
precursors of SPM, such as EPA and DHA, do not activate these
receptors (Figure 2) (Arita et al., 2005; Chiang et al., 2012; Dalli
et al., 2013) but, rather, other receptors (i.e., GPR120), although
these sensors are activated by these essential fatty acids at high
micromolar concentrations. Other fatty acids, including mono-
unsaturated fatty acids (e.g., palmitoleic acid and oleic acid)
also appear to activate GPR120 (Oh et al., 2010), and, thus, re-
ceptor-mediated actions of fatty acids remain to be elucidated.
During in vivo studies evaluating SPM bioactions, it was found
that, in addition to halting PMN recruitment and promoting
macrophage phagocytosis, SPMs also enhance phagocyte
efflux from inflamed tissues to draining lymph nodes in order to
aid in host defense. When leukocytes exit the inflamed site or
exudate, they traverse perinodal adipose tissue en route to local
lymph nodes (Schwab et al., 2007). Excessive and persistent
inflammation during this lipopassage (or failure of leukocytes to
reach the lymphatics [Schwab et al., 2007] that, hence, get
stuck within adipose) can lead to adipose inflammation, which
may contribute to metabolic syndrome (see below). BecauseCell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc. 23
Figure 2. Proresolving Receptors and Biological Actions of SPMs
E series resolvins (RvE1 and RvE2) are agonists for ChemR23/ERV and antagonists for the leukotriene B4 receptor, BLT-1. Lipoxin A4 (LXA4) and D series
resolvins, RvD1, RvD3, and RvD5 (RvD1 structure shown) are agonists for GPR32/DRV1 and ALX/FPR2. Acting via these specific receptors, SPMs elicit their
biological actions on leukocytes, which include the attenuation of PMN trafficking, activation, and inflammatory gene transcription as well as the stimulation of
macrophage phagocytosis of both apoptotic cells and bacteria.
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diverse diseases, it is likely that SPMs may play a critical role in
preventing chronic inflammatory diseases and, potentially,
organ fibrosis. We refer readers to detailed recent reviews
covering SPM biosynthesis (Bannenberg et al., 2005), stereose-
lective receptor-dependent actions, and total organic synthesis
(Serhan, 2007; Serhan and Petasis, 2011; Serhan and Chiang,
2013), given that a comprehensive analysis of these topics is
outside of the scope of this review. Here, we evaluate recent
evidence indicating that a failure of resolution and SPM biosyn-
thesis contribute to chronic inflammation in the context of
nutrient excess and that resolution agonists such as SPMs
improve several clinically relevant outcomes in metabolic syn-
drome. This work posits that resolution agonists may represent
a novel pharmacologic genus that is distinct from traditional
anti-inflammatory therapies that impair host defense. Impor-
tantly, it also suggests that SPMs may be more effective from
a therapeutic standpoint than parent omega-3 fatty acids, which
are subject to multiple downstream metabolic checkpoints for
eliciting their biological effects.
Defective Resolution of Inflammation in Metabolic
Syndrome
Effector cells of the innate immune system, including PMNs and
macrophages, are sensitive to changes in nutrient tone, and
dysregulated systemic metabolism leads to chronic activation
and inflammatory signaling in these cells (Lumeng and Saltiel,24 Cell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc.2011). Likewise, robust inflammatory signaling occurs in nonim-
mune cells such as endothelial cells and adipocytes during
states of nutrient stress (Hotamisligil, 2006). As such, chronic
inflammation is associated with several diseases characterized
by systemic alterations in metabolism, such as obesity, dia-
betes, and atherosclerosis (Rocha and Libby, 2009; Bornfeldt
and Tabas, 2011). Although persistent metabolic dysfunction
drives inflammation, it is clear that inflammation in turn could
disrupt metabolic homeostasis. Thus, it is plausible that a defi-
ciency in the processes that normally resolves inflammation
after the induction of an inflammatory response could underlie
the vicious feedforward cycle observed in chronic states of
overnutrition.
Hypercholesterolemia
Hypercholesterolemia and subendothelial retention of choles-
terol-rich oxidized lipoproteins in arteries lead to the recruitment
and activation of macrophages, forming atherosclerotic lesions.
Macrophage uptake of modified lipoproteins, coupled with
defective cholesterol efflux through ATP binding cassette trans-
porters (i.e., ABCA1 and G1), leads to the formation of choles-
terol-loaded macrophage foam cells that persist in the vessel
wall, initiate robust proinflammatory signaling and eventually un-
dergo postapoptotic secondary necrosis due to defective egress
or clearance by healthy phagocytes (Rocha and Libby, 2009;
Bornfeldt and Tabas, 2011). It is currently held that deficient ef-
ferocytosis (apoptotic cell clearance) is related to the evolution
of benign early fatty streaks (Merched et al., 2011) to more
Cell Metabolism
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failure to promote efferocytosis may be a key determinant of
lesion progression (Bornfeldt and Tabas, 2011). Although multi-
ple mechanisms could underlie these defects, including a defi-
ciency of receptors and bridgingmolecules involved in apoptotic
cell uptake (i.e., Mertk and Mfge8), a lack of stimulatory media-
tors of efferocytosis could also play an important role (see below)
(Bornfeldt and Tabas, 2011; Han and Ravichandran, 2011). In
addition to macrophages, recent evidence indicates that PMNs
also contribute to plaque progression and destabilization (Weber
et al., 2008). In humans and animal models, atherosclerosis is
associated with increased circulating PMN numbers, which con-
tributes to plaque progression by increasing the generation of
reactive intermediates from high levels of myeloperoxidase and
promoting monocyte recruitment and dendritic cell (DC) activa-
tion (Della Bona et al., 2013). Moreover, the accumulation of
apoptotic PMNs in plaques could result from deficient macro-
phage-mediated clearance. Thus, persistent recruitment of leu-
kocytes coupled with a failure of phagocyte egress suggests a
lack of endogenous proresolving mediators that are normally
operative during acute inflammation.
Plasma levels of proresolving lipid mediator LXA4 (aspirin-trig-
gered form; ATL) inversely correlate with the development of
both peripheral and coronary atherosclerosis in humans (Ho
et al., 2010). This inverse relationship between ATL and periph-
eral atherosclerosis remains significant even after adjusting for
age, gender, and high-sensitivity C-reactive protein. In mouse
atherosclerosis models, macrophage-specific overexpression
of a biosynthetic enzyme important in SPM biosynthesis (i.e.,
12/15-LOX) decreases lesion formation in apolipoprotein E-defi-
cient mice, and macrophages isolated from these transgenic
mice biosynthesize more LXA4 than WT (Merched et al., 2008).
In macrophages, LXA4 and other SPMs, including RvD1 and
PD1 blunt production of cytokines such as CCL2, IFNg, KC
(murine isoform of IL-8), and IL-1b. In contrast, the phagocytosis
of apoptotic cells is markedly enhanced by all three SPMs. In
addition to macrophage-targeted actions, SPMs also reduce
adhesion receptor expression (i.e., VCAM-1 and P-selectin)
and chemokine production in isolated endothelial cells stimu-
lated with TNFa. These atheroprotective actions were extended
in more recent studies demonstrating that D-series resolvins are
generated during vascular injury in vivo and that therapeutic
administration of resolvins decreases intimal hyperplasia and
leukocyte trafficking to injured arteries (Miyahara et al., 2013).
In vitro studies demonstrated that SPMs block proliferation,
migration,monocyte adhesion, and inflammatory signaling in hu-
man primary vascular smooth muscle cells in a receptor-depen-
dent manner. Collectively, these findings demonstrate that the
perpetuating inflammatory events that lead to advanced athero-
sclerosis may be related to the defective biosynthesis of media-
tors that resolve local inflammation and promote efferocytosis.
Importantly, they highlight that resolution agonists (e.g., resol-
vins) may be novel immunomodulators that could ‘‘resolve’’
chronic inflammation induced by hypercholesterolemia.
Nonesterified Free Fatty Acids and Triglycerides
Similar to hypercholesterolemia, high circulating levels of nones-
terified free fatty acids (FFAs) associated with obesity and type 2
diabetes also lead to the profound activation of inflammatory
signaling in both immune and nonimmune cells. The liberationof FFAs via lipolysis of triglyceride stores in insulin-resistant
adipocytes drives macrophage recruitment to hypertrophied
adipose tissue and promotes classical activation, whereas
even an acute elevation of FFAs has been shown to increase
macrophage accumulation in the heart (Ko et al., 2009; Gregor
and Hotamisligil, 2011). Ectopic triglyceride accumulation in
other tissues, such as the skeletal muscle and liver, is also asso-
ciated with increased inflammatory signaling and leukocyte
accumulation. Results from several studies demonstrate that
pattern recognition receptors important in sensing exogenous
pathogens are activated by FFAs in micromolar concentrations.
For instance, high levels of saturated FFAs activate TLR2 and
TLR4, which leads to immune cell activation, production of in-
flammatory cytokines, and defective insulin signaling (Nguyen
et al., 2007). Indeed, TLR4-null mice are protected against insulin
resistance and adipose inflammation in response to acute FFA
challenge (Shi et al., 2006). More recently, nod-like receptors
(NLRs), which are intracellular receptors and key components
of inflammasome, are implicated as sensors of FFAs. Activation
of the NLRP3-ASC inflammasome by FFAs in hematopoietic
cells leads to the production of IL1-b and IL-18, and mice defi-
cient in inflammasome components, namely Pycard and Nlrp3,
are protected from systemic insulin resistance and hyperglyce-
mia in the context of obesity (Wen et al., 2011). Hence, nutrient
sensing by pattern recognition receptors sustains inflammation,
which contributes to the development of insulin resistance. How-
ever, it should be noted that several other mechanisms have
been proposed to mediate the diverse signaling roles of FFAs,
such as alterations inmembrane fluidity, nuclear receptor activa-
tion, and lipid raft formation (Hotamisligil, 2006; Li et al., 2009).
Moreover, because circulating FFAs encompass a diverse array
of both saturated and unsaturated fatty acids, their overall
inflammatory potential is likely to be regulated by the relative
distribution of FFA species in vivo.
Consistent with increased inflammatory signaling via elevated
FFAs in leukocytes, we recently documented that saturated
FFAs promote PMN survival during acute inflammation
(Hellmann et al., 2013). We utilized an acute model of sterile
peritonitis because we established a set of resolution indices
(Bannenberg et al., 2005) that serve as useful criteria for estab-
lishing how specific components of resolution are modulated in
different scenarios (e.g., experimental inflammation-modifying
drugs, etc.). These indices include Jmax, which represents the
magnitude of maximal PMN infiltration; Tmax (the time point at
which PMNs reach their maximum levels), T50 (the time point at
which PMNs decline to half of their maximum value), and Ri (res-
olution interval; the period of time during which PMNs decrease
to half of their maximum value) (Bannenberg et al., 2005). Using
this system, we determined that, despite similar infiltration of
PMNs during acute inflammation in obese diabetic mice,
PMNs accumulate during the phase at which they normally un-
dergo apoptosis and are cleared from the inflamed site (Figures
3A and 3B). The incubation of human PMNs with saturated FFAs
promotes signaling via the extracellular signal-related kinase
pathway and decreases caspase-3 cleavage—effects that are
similar to that of lipopolysaccharide (LPS)-mediated activation
of TLRs. Given that increased PMN survival is associated with
the delayed resolution of inflammation, these results suggest
that chronically elevated FFAs may modulate the resolution ofCell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc. 25
Figure 3. Altered Resolution of Inflammation in Diabetic Wounds
(A) Cellular events during a normal acute inflammatory response depicting the rapid macrophage-dependent clearance of apoptotic neutrophils (PMN).
Established resolution indices are shown, withJmax representingmaximumPMN infiltration, Tmax representing the time point at which PMN reach their maximum
levels, T50 representing the time point at which PMN decline to half of their maximum value, and Ri representing the resolution interval, the period of time during
which PMNs decrease to half of their maximum value; see Bannenberg et al. (2005) for details.
(B) Altered resolution of acute inflammation in the context of obesity and diabetes in which PMN apoptosis is delayed andmacrophage efferocytosis is defective.
(C) Depiction of defects in the wound-healing program in diabetes, including persistent leukocyte and apoptotic cell accumulation and defective wound closure.
(D) Enhancement of wound healing in diabetes by SPMs by promoting macrophage-mediated apoptotic cell clearance and re-epithelialization.
Cell Metabolism
Reviewacute inflammation (Serhan et al., 2007). Interestingly, other
studies have recently documented that proresolving lipid medi-
ators, such as RvE1, override survival signaling induced by in-
flammatory mediators (i.e., serum amyloid A) and, thus, enhance
resolution (El Kebir et al., 2012). Hence, in contrast to rapid
apoptosis and clearance of PMNs during acute inflammation in
health, the altered metabolic environment in obesity and type 2
diabetes leads to chronic leukocyte accumulation in part from
prolonged survival at sites of inflammation; e.g., within the adi-
pose tissue. This continued presence of activated PMNs can
precipitate unintentional tissue injury.
Along with promoting low-grade inflammation, nutrient excess
also paradoxically impairs host defense and promotes leukocyte
dysfunction. Indeed, results from several studies show that both
obesity and diabetes are associated with increased susceptibil-
ity to respiratory, skin, odontogenic, and postsurgical nosoco-
mial infections (Falagas and Kompoti, 2006). As noted, innate
immune cells, such as macrophages and PMNs, play critical
roles in bacterial containment via phagocytosis and lysosomal-
dependent bacterial killing. Defects in macrophage phagocy-
tosis have been established in animal models of obesity and
diabetes, and the exposure of macrophages to saturated FFAs26 Cell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc.induces defects in both FcR-mediated phagocytosis and
apoptotic cell uptake (O’Brien et al., 2002, 2006; Li et al., 2009;
Khanna et al., 2010; Hodgson et al., 2011). Recently, we demon-
strated that macrophage-mediated clearance of apoptotic thy-
mocytes, as well as IgG-opsonized zymosan, is defective in
obese diabetic mice (Hellmann et al., 2013; Tang et al., 2013).
In these studies, we also observed a persistence of apoptotic
PMNs and zymosan in the peritoneum during acute sterile
inflammation. Given that the macrophage-mediated clearance
of apoptotic cells is required to resolve inflammation, defects
in this specific process in obesity and diabetes suggests that
endogenousmediators involved in active stimulation of immuno-
logically silent efferocytosis are diminished (Figures 3A and 3B).
These results in the setting of acute sterile inflammation largely
recapitulate findings in models of chronic inflammation, such
as atherosclerosis (see above), suggesting that this and related
acute models may be useful in identifying molecular events in
inflammation that are dysregulated by nutrient excess.
Although the precise molecular mechanisms underlying de-
fects in macrophage phagocytosis induced by saturated FFAs
are not complete, recent results indicate that autocrine produc-
tion of prostanoids, such as PGE2 and PGD2 may play a role.
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tosis by receptor-mediated activation of cAMP pathway, effects
that are in part due to the downstream activation of phosphatase
and tensin homolog on chromosome 10 and subsequent inacti-
vation of phosphatidyl inositol 3-kinase (PI3K) (Canetti et al.,
2007). Our recent results demonstrate that FFAs drive inflamma-
tory signaling, which leads to the upregulation of COX-2 and
subsequent production of PGE2 and PGD2 in macrophages,
and that autocrine actions of these prostanoids are causally
related to defective phagocytosis induced by FFAs (Hellmann
et al., 2013). Li et al. (2009) found that the ratio of omega-6 to
omega-3 polyunsaturated fatty acids in macrophages may be
an important determinant of defective phagocytosis induced
by FFAs. Although altered uptake of apoptotic cells was evident
in macrophages incubated with FFAs, these defects were
restored by the addition of EPA and DHA. Although alterations
in membrane fluidity could play a role in the regulation of phago-
cytosis at higher local concentrations by these diverse fatty
acids (Calder, 2013), it is also possible that substrate diversion
to anti-inflammatory and proresolving lipid mediators may partly
underlie the protective effects of omega-3 polyunsaturated fatty
acid in this context, given that SPMs are biosynthesized during
macrophage phagocytosis (Chiang et al., 2012; Serhan and
Chiang, 2013). In support of this view, defects in diabetic macro-
phage phagocytosis are acutely reversed by RvD1 in a receptor-
dependent manner (Tang et al., 2013). The activation of ALX/
FPR2 by RvD1 blocks cAMP accumulation via coupling ALX/
FPR2 to Gai and the subsequent inhibition of adenylate cyclase
(Krishnamoorthy et al., 2010; Hellmann et al., 2013; Tang et al.,
2013). Given that cAMP-PKA signaling impairs phagosome for-
mation at the level of PI3K, it is likely that the chronic activation
of this pathway may underlie an inability of macrophages to un-
dergo phagocytosis in the context of nutrient excess. Indeed,
FFAs alter tyrosine phosphorylation of the regulatory p85 subunit
of PI3K inmacrophages, which is related to defective efferocyto-
sis (Li et al., 2009). This dysfunction and its correction by SPMs is
potentially of high significance, given that defects in phagocy-
tosis lead to apoptotic cell accumulation and bacterial prolifera-
tion and are thus associated with atherosclerosis, autoimmunity
and increased susceptibility to infections. These results also
highlight that temporal imbalances between proinflammatory
versus proresolving lipid mediators sustains inflammation.
Hyperglycemia
The defining metabolic feature of both type 1 and 2 diabetes is
hyperglycemia, which is due to the deficient insulin production
or systemic insulin resistance, respectively. Because of the high-
ly integrated nature of glucose and lipid metabolism, it is not sur-
prising that the changes in lipid metabolism in states of obesity
and nutrient excess lead ultimately to systemic hyperglycemia.
The common downstream effector in these conditions of nutrient
stress is uncontrolled inflammation, which most likely explains
the strong association of diabetes with increased risk of inflam-
matory diseases, such as cardiovascular disease and cancer.
With respect to cardiovascular disease, recent studies suggest
that hyperglycemia regulatesmyelopoiesis and sustainedmono-
cyte recruitment to atherosclerotic lesions (Nagareddy et al.,
2013). Interestingly, this enhanced myelopoiesis results from
the increased production of inflammatory mediators (S100A8)
released by PMNs. Other recent results demonstrate that mac-rophages isolated from type 1 diabetic mice exhibit an inflamma-
tory phenotype associated with the increased expression of
long-chain acyl-CoA synthetase 1 (ACSL1) and that myeloid
deletion of Acsl1 decreases atherosclerosis in the context of
type 1 diabetes (Kanter et al., 2012). Mechanistically, hypergly-
cemia induces ACSL1 in macrophages, which results in
increased AA-CoA esters and the production of inflammatory
lipid mediators, such as PGE2. The production of PGE2 en-
hances inflammatory signaling in macrophages and is markedly
reduced in Acsl1-deficient macrophages. These results are in
alignment to those obtained with macrophages incubated with
the FFAs reviewed above, indicating that sustained production
of proinflammatory lipid mediators may be a common down-
stream pathway in macrophages activated by nutrient stress.
Similar to elevated levels of FFAs, hyperglycemia also pro-
motes leukocyte dysfunction. Hyperglycemia impairs PMN
chemotaxis, yet it increases the production of superoxide and
inflammatory cytokines. In Akita mice, which are a model of
human type 1 diabetes, increased PMN adherence to the micro-
vasculature and associated tissue damage were observed in a
model of ligature-induced bone loss (Gyurko et al., 2006). In
macrophages, hyperglycemia impairs the phagocytosis of both
apoptotic cells and bacteria, and nonobese diabetic mice have
a deficiency in the clearance of apoptotic cells (Abrass and
Hori, 1984; O’Brien et al., 2002; O’Brien et al., 2006). Given
that both hyperglycemia and elevated FFA levels initiate inflam-
matory signaling, which gives rise to PGE2 production in macro-
phages (see above), these results suggest that autocrine actions
of proinflammatory lipid mediators may underlie phagocyte
defects in the context of nutrient excess. Thus, leukocyte
dysfunction leading to persistent inflammation and altered reso-
lution are common features of nutrient excess and play a causal
role in promoting chronic metabolic disease.
Delayed Resolution of Inflammation in Diabetic Wounds
The complete resolution of tissue injury involves a temporally
coordinated program that is evolutionarily conserved. After
tissue damage from blunt trauma, surgical incision, burn, or
ischemia, a prompt response is mounted that has the ultimate
goal of returning tissue(s) to their previous state. Although, in
some tissues and organisms, the regeneration process is com-
plete, in most cases, a fibrotic scar is left at the site of injury after
the host-protective inflammatory response has resolved
(Figure 1A). After primary hemostasis, there is an early infiltration
of PMNs, which carry an armament for destroying foreign in-
vaders. As noted above, endogenous counterregulatory media-
tors such as SPMs regulate the magnitude of the PMN infiltrate
appropriate for the level of injury and/or pathogen load. Sub-
sequent infiltration of macrophages leads to the clearance of
apoptotic cells and tissue debris, and macrophages also assist
with pathogen eradication and participate in notifying the adap-
tive immune system of a potential threat through differentiation
into antigen-presenting cells (i.e., monocyte-derived DCs). Mac-
rophages persist in wounds for an extended period of time and
exist in multiple phenotypic states in order to carry out specific
tasks in the wound-healing program, such as tissue remodeling,
revascularization, and fibrosis (Mosser and Edwards, 2008;
Brancato and Albina, 2011). It has recently been shown that
so-called ‘‘inflammatory’’ monocytes, which in mice are definedCell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc. 27
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differentiate into reparative monocytes andmacrophages during
the resolution of fibrosis and tissue regeneration (Ramachandran
et al., 2012; Godwin et al., 2013; Nahrendorf and Swirski, 2013;
Wynn et al., 2013). Ultimately, blood supply is restored to the
injured tissue, and carefully orchestrated tissue fibrosis ensues.
In the case of cutaneous wounds, re-epithelialization and the
reinstatement of barrier function proceeds with the extent of
scar tissue formation related to the depth of the wound.
Several steps in the intricately orchestrated wound-healing
program are disrupted in the context of metabolic disease,
and defective wound healing (accompanied by tissue necrosis
and infection) is one of the most prominent clinical manifesta-
tions of diabetes (Jeffcoate and Harding, 2003). Because
of peripheral neuropathies and both macrovascular and micro-
vascular disease, diabetics often sustain wounds in the extrem-
ities. Insufficient blood supply increases susceptibility to wounds
and also impairs wound healing, and, thus, clinical management
of tissue vascularization through vascular and endovascular
surgical procedures is often necessary in order to prevent
chronic ischemia. Obesity and diabetes are both associated
with increased risk of infection in open wounds, which can be
related to defects in leukocyte-mediated pathogen killing and
containment (Figure 3C). In fact, diabetic wounds are usually
characterized by excessive leukocyte accumulation, indicating
that leukocyte dysfunction and failure to promote phagocyte
egress may be important determinants of delayed wound
healing in diabetes (Figure 3C) (Wetzler et al., 2000; Khanna
et al., 2010).
Recently, we reported that SPM biosynthetic pathways are
perturbed in the wounds of obese diabetic mice. In a murine
model of cutaneous excisional wound healing, obese diabetic
mice had significant defects in wound closure, and this was
associated with decreased conversion of DHA to intermediates
and pathway biomarkers involved in the biosynthesis of mare-
sins, resolvins, and protectins; e.g., 14-HDHA and 17-HDHA
(Tang et al., 2013). Leukocytes and apoptotic cells accumulate
in the wounds of diabetic mice, and, because the clearance of
apoptotic cells is a primary feature of active resolution of inflam-
mation, we asked whether SPMs would enhance apoptotic
cell clearance and wound closure. Indeed, local application of
RvD1 significantly decreases apoptotic cells and macrophages
in diabetic wounds, and this translates into enhanced wound
closure and granulation tissue formation (Figure 3D). RvD1 res-
cues the defective clearance of apoptotic cells in the thymus
of diabetic mice, indicating that correcting phagocyte defects
is a primary protective action of SPMs in diabetes. In addition
to the clearance of apoptotic cells, RvD1 rescues defective
FcR-mediated phagocytosis, suggesting that SPMs can also
serve as effective adjunctive therapeutics to antibiotics in the
context of diabetic wound infection. Along these lines, cotreat-
ment of wild-type mice with ciproflaxacin and RvD5 significantly
enhances survival in the context of Escherichia coli infection in
comparison to antibiotic treatment alone, whereas RvD1,
RvD5, and PD1 enhance vancomycin-mediated clearance of
Staphylococcus aureus during skin infection (Chiang et al.,
2012). Altogether, these findings suggest that defective SPM
biosynthesis in diabetesmay be related to increased susceptibil-
ity to wound infection and prolonged inflammation.28 Cell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc.In addition to macrophage phagocytosis, SPMs regulate other
distinct cellular events during the wound-healing program and
may have actions on nonimmune cells as well. For instance,
RvD1 enhances human keratinocyte migration in vitro, which is
a critical step in wound closure (Norling et al., 2011). Lipoxyge-
nase-mediated biosynthesis of MaR1, which is the newest mem-
ber of the SPM genus, was recently uncovered during tissue
regeneration in brown planaria (Dugesia tigrina) subject to surgi-
cal injury (Serhanet al., 2012). AddingsyntheticMaR1backsignif-
icantly enhances tissue regeneration, suggesting that SPMs play
an evolutionarily conserved role in wound remodeling and tissue
regeneration. As noted, resolvins, specifically RvD1, RvD2, and
RvD5, potently regulate bacterial containment by phagocytes,
and, in support of this notion,RvD2was found toenhancesurvival
in a rodentmodel of cutaneous burn injury (Bohr et al., 2013; Kur-
ihara et al., 2013) and sepsis (Spite et al., 2009). Treatment of burn
wounds with RvD2 largely prevents dermal necrosis and pre-
serves the vasculature, whereas untreated mice show progres-
sive tissue necrosis and thrombosis in the deep dermal vascular
network. Mechanistically, RvD2 rescues defective directional
migration of PMNs isolated from burn wounds and simulta-
neously decreases proinflammatory cytokine production by
PMNs. These findings suggest that SPM display diverse roles in
wound-healing programs and that they may be effective media-
tors in modulating innate cells (e.g., phagocytes) that could
rescue defective wound healing in the context of metabolic dis-
ease and prevent tissue loss and susceptibility to infection.
Nonresolving Adipose Tissue Inflammation
Adiposity is a dominant risk factor for the metabolic syndrome
and related comorbidities. In mammals, the two types of fat tis-
sue are white adipose tissue (WAT) and brown adipose tissue
(BAT). WAT is characterized by the presence of adipocytes
containing large unilocular lipid droplets, whereas BAT is mainly
composed by multiloculated adipocytes containing large
numbers of mitochondria (Rosen and Spiegelman, 2006). WAT
is widely distributed through the body, and its main function is
to store excess energy as triglycerides. In contrast, BAT is
located in discrete pockets and is specialized to generate heat
by dissipating chemical energy and counteracting hypothermia
(Rosen and Spiegelman, 2006). However, BAT is difficult to
find in adult humans, given that brown fat pads existing within
the posterior neck in neonatal humans to provide cold adaptive
nonshivering thermogenesis for newborns are lost soon after
birth (Cristancho and Lazar, 2011).
WAT is mainly recognized for its role as a major secretory
organ responsible for lipolysis and release of fatty acids in the
circulation. WAT is the major source of fatty acids that are
used as energy substrates for generating ATP (Redinger,
2009). Until the last decade, energy storage and lipolysis were
seen essentially as the unique roles of WAT. Nowadays, WAT
is regarded as a highly active metabolic tissue and an important
endocrine organ involved in the balance of body homeostasis
beyond the paradigm of fuel storage. Indeed, since the cloning
of the ‘‘ob’’ gene coding for leptin in 1994 (Zhang et al., 1994),
an ever-increasing number of hormones, signaling peptides,
and lipid mediators secreted from WAT, now numbering more
than 50 different molecular entities, have been identified.
These molecules, collectively known as adipokines, are widely
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tions, blood pressure homeostasis and metabolic processes
such as appetite and satiety as well as glucose and lipid
metabolism.
Adiposity develops when food availability exceeds the meta-
bolic demand (‘‘nutrient excess’’). In this setting, adipocytes
expand nearly 1,000-fold in volume and 10-fold in diameter in
order to store the excess of fuel as triglycerides (Redinger,
2009). In the setting of obesity, an imbalance between oxygen
supply and demand in enlarged adipocytes inadvertently trig-
gers tissue hypoxia, which initiates a cascade of events leading
to chronic ‘‘low-grade’’ inflammation in the adipose tissue (Eltz-
schig and Carmeliet, 2011). This ‘‘low-grade’’ inflammation can
be regarded as a long-term inflammatory response triggered
by nutrients and metabolic surplus and, therefore, is also known
as ‘‘metabolic-triggered inflammation’’ or ‘‘metainflammation’’
(Hotamisligil, 2006). Metabolic inflammation is usually not sys-
temic, but it may affect disease processes in target organs
such as the liver and pancreas and increase the incidence of
classical inflammatory diseases such as rheumatoid arthritis
(Jeppesen, 2011; Gukovsky et al., 2013). It involves molecules
and pathways similar to those of classical inflammation, but, in
this case, these signals play a dual role as inflammatory media-
tors as well as regulators of energy storage and metabolism. A
rise in proinflammatory adipokines such TNFa, IL-6, IL-1b,
MCP-1, leptin, and resistin, accompanied by a reduction in the
anti-inflammatory and insulin-sensitizing adipokine adiponectin,
has been reported to signal the onset of metabolic dysfunction
(Ouchi et al., 2011). This unbalanced secretion of inflammatory
adipokines results in the recruitment of circulating inflammatory
cells, especially macrophages, into WAT, thus perpetuating an
inflammatory vicious cycle.
The ability of adipose tissue to produce bioactive local medi-
ators derived from enzymatic oxygenation of polyunsaturated
fatty acids was first described in the late 1960s (Shaw and Ram-
well, 1968). PGE2 is an abundant COX product in adipose tissue,
where it plays a role in adipogenesis and lipolysis, although its
role in WAT inflammation remains unclear. Interestingly, 5-LOX
products are identified to play a proinflammatory role in adipose
tissue. Indeed, all enzymes necessary for the formation of 5-LOX
products (5-LO, 5-LO-activating protein [FLAP], LTA4 hydrolase,
and LTC4 synthase), as well as receptors involved in LT signaling
(BLT-1, BLT-2, CysLT1, and CysLT2), are present in adipose tis-
sue (Horrillo et al., 2010). FLAP overexpression and excessive
generation of 5-LOX products are common findings in adipose
tissue of obese patients and animals with insulin resistance
(Ba¨ck et al., 2007; Horrillo et al., 2010; Chakrabarti et al.,
2011). In obese adipose tissue, a direct connection between
LTB4 and enhanced release of the adipokines, MCP-1 and IL-6
has been established, and mice deficient in LTB4 receptor
BLT-1 show reduced monocyte recruitment to hypertrophied
adipose tissue (Horrillo et al., 2010; Spite et al., 2011). Consis-
tently, the inhibition of the 5-LOX pathway with a selective
FLAP inhibitor or genetic deletion of BLT-1 alleviates adipose tis-
sue inflammation and insulin resistance in obesity (Horrillo et al.,
2010; Spite et al., 2011). In addition to 5-LOX, inflammatory lipid
mediators generated from AA via 12/15-LOX (i.e., 12-HETE) also
play an important role in the development of adipose tissue
inflammation in obesity (for review, see Cole et al., 2013). Thisfurther emphasizes that lipid mediator pathways are skewed
toward the continued production of inflammatory lipid mediators
in the context of nutrient excess and that the ‘‘lipid mediator
tone’’ (see below) may be an important determinant as to
whether inflammation resolves or persists in obesity.
In addition to the heightened production of proinflammatory
lipid- and peptide-derived chemical mediators (i.e., LTB4, IL-6,
TNFa, and MCP-1), unresolved inflammation in obese adipose
tissue also appears to be associated with impaired biosynthesis
of anti-inflammatory mediators. Indeed, obesity entails a consis-
tent reduction in the circulating levels of adiponectin, one of the
few adipokines that possesses anti-inflammatory and insulin-
sensitizing properties (Trayhurn and Wood, 2005). Notably, a
deficit in SPM levels is also present in adipose tissues from
patients with metabolic syndrome and experimental models of
obesity and insulin resistance. In particular, recent studies
have uncovered the existence of a marked deficit in PD1 and
its precursor 17-HDHA in subcutaneous fat from patients with
peripheral vascular disease in whom the inflammatory status in
adipose tissue is remarkably exacerbated in comparison to
healthy subcutaneous fat (Cla`ria et al., 2013). In this study,
LC-MS/MS-based metabolo-lipidomic analyses of fat from
selected human anatomic locations identified unique signature
profiles in the content of bioactive lipid mediators. Importantly,
these analyses demonstrated a heterogeneous capacity for
SPM biosynthesis among different adipose tissue depots, a
higher activation of resolution circuits occurring in perivascular
fat in comparison to subcutaneous fat (Cla`ria et al., 2013). This
is relevant for vascular pathologies because, for its tissue
mass and anatomic proximity surrounding systemic vessels,
perivascular adipose tissue plays an emerging role in vascular
biology homeostasis. A failure in the endogenous anti-inflamma-
tory peptide annexin A1 to respond to increased systemic
inflammation has also been demonstrated in human obesity
(Kosicka et al., 2013). At the experimental level, a deficit in tissue
SPM levels (RvD1, PD1, and 17-HDHA) has been characterized
in inflamed visceral and subcutaneous fat compartments from
ob/ob obese and db/db obese diabetic mice (Gonza´lez-Pe´riz
et al., 2009; Neuhofer et al., 2013). Given that SPM autacoids
are made locally, act in their surrounding tissue milieu, and are
metabolically inactivated, the loss of SPM in obese adipose tis-
sue can be the consequence of omega-3 fatty acid deficiency in
the tissue, which are substrates for SPM biosynthesis (Canetti
et al., 2007). Along these lines, the transgenic restoration of
omega-3 fatty acids reversed the inefficient resolution capacity
in adipose tissue from obese mice (White et al., 2010). Alterna-
tively, the loss of SPMs in obesity may reflect accelerated tissue
SPM conversion and clearance to inactive further metabolites
because 15-PG-dehydrogenase (also known as eicosanoid
oxidoreductase), a key enzyme in SPM inactivation, is markedly
upregulated in obese adipose tissue (Cla`ria et al., 2012). In adi-
pose tissue, both RvD1 and RvD2 are each further metabolically
converted to oxo-resolvin products, some of which appear inac-
tive (Cla`ria et al., 2012). It is noteworthy that SPM deficiencies in
obesity appear to be a generalized defect in all metabolic tis-
sues, given that, in addition to adipose, deficiencies are noted
in the liver, cutaneous wounds, and skeletal muscle (White
et al., 2010; Tang et al., 2013). Collectively, these findings are
consistent with the notion that unresolved chronic ‘‘low-grade’’Cell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc. 29
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priate resolution-capacity allowing the inflammatory response
to proceed without controlled checkpoints.
Consistent with the notion that defective SPM biosynthesis
promotes adipose tissue inflammation, the administration of
exogenous SPM successfully rescues the impaired resolution
capacity of obese adipose tissue. In this regard, the administra-
tion of nanogram doses of RvD1 to db/db obese diabetic mice
improves glucose tolerance, decreases fasting blood glucose,
and increases insulin-stimulated Akt phosphorylation in adipose
tissue (Hellmann et al., 2011). This SPM also reduces the forma-
tion of crown-like structures rich in inflammatorymacrophages in
adipose tissue. Similarly, intraperitoneal (i.p.) injection (nano-
gram amounts) of RvE1 to obese ob/obmice confers significant
insulin-sensitizing effects by mechanisms related to the AMPK-
adiponectin axis and the induction of GLUT-4 and IRS-1 expres-
sion (Gonza´lez-Pe´riz et al., 2009). Also, 17-HDHA treatment (i.p.
injection of nanogram doses) reduces adipose tissue expression
of inflammatory cytokines (MCP-1, TNFa, IL-6, and osteopontin),
increases adiponectin expression, and improves glucose toler-
ance in parallel to insulin sensitivity in db/db obese diabetic
mice (Neuhofer et al., 2013). Ex vivo, in fat explants, RvD1 and
RvD2 each rescue the impaired phenotype of obese adipose
tissue by enhancing the expression and secretion of adiponectin
in parallel with decreasing the secretion of proinflammatory
adipokines and cytokines including leptin, TNFa, IL-6, and
IL-1b (Cla`ria et al., 2012). Using adipose tissue explants from
aging female mice as a model of age-associated adipose inflam-
mation, Bo¨rgeson et al. (2012) recently discovered that LXA4
in nanomolar concentrations decreases IL-6 while restoring
GLUT-4 and IRS-1 expression, indicating improved inflamma-
tion and insulin sensitivity. Additional investigations reveal that
LXA4 preserves Akt signaling and glucose uptake in cultured
adipocytes. In human monocyte-adipocyte coincubations,
both RvD1 and RvD2 reduce MCP-1- and LTB4-stimulated
monocyte adhesion to adipocytes as well as monocyte transa-
diposemigration (Cla`ria et al., 2012). These interactions between
monocytes and adipocytes are likely events in the progression of
inflamed adipose tissue (see below). Importantly, RvD1 stimu-
lates macrophage phagocytosis and enhances the phagocytic
activity of macrophages isolated from the adipose tissue stromal
vascular cell fraction (Titos et al., 2011). A summary of the main
actions of SPMs uncovered to date in adipocytes and macro-
phages from the stromal vascular cell fraction is illustrated in
Figure 4. Altogether, these findings suggest that the lack of
intrinsic capacity of adipose tissue to produce endogenous
‘‘stop signals’’ required in the resolution of inflammation is a
critical factor(s) that can contribute to obesity-linked inflamma-
tion and insulin resistance.
An intriguing aspect of adipose tissue inflammation is that the
inflammatory response in this organ and tissue appears to be a
unique process driven in large part by tissue macrophages
(Lumeng and Saltiel, 2011). Indeed, the presence of an increased
number of adipose-tissue-infiltrating macrophages, which form
the characteristic ‘‘crown-like structures’’ that surround necrotic
adipocytes and scavenge adipocyte debris, is a hallmark of
obesity (Cancello et al., 2005). Although enlarged adipocytes
were initially thought to be the cellular source of proinflammatory
mediators in obesity, it was later established that infiltrated mac-30 Cell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc.rophages in obese fat are the major driver of exacerbated
production of proinflammatory mediators (Odegaard and
Chawla, 2013). The contribution of other inflammatory cell types,
including T lymphocytes and eosinophils, to adipose tissue
inflammation and homeostasis has also been acknowledged
(Odegaard and Chawla, 2013). In addition to the augmented infil-
tration of macrophages into adipose tissue, obesity also induces
a phenotypic switch in these cells toward the classically acti-
vated M1 phenotype (Lumeng and Saltiel, 2011). Depending on
the disease stage and the signals they are exposed to, macro-
phages are broadly characterized by their activation (polariza-
tion) status according to the M1-M2 classification system
(Mosser and Edwards, 2008). On the basis of this classification,
the M1 designation is reserved for classically activated macro-
phages after stimulation with IFNg and LPS, whereas the
M2 designation is applied to the alternatively activated macro-
phages after in vitro stimulation with IL-4 and IL-13. M1
macrophages display enhanced proinflammatory biosynthetic
capacity and increased superoxide anion (O2
) levels (Mosser
and Edwards, 2008). Conversely, M2 macrophages produce
less proinflammatory cytokines and are essential for tissue repair
and resolution of inflammation. M1-M2macrophage polarization
can be easily monitored in rodents by assessing the expression
of selected markers. M1-associated genes include inducible ni-
tric oxide synthase (iNos) and classical proinflammatory media-
tors such as Tnfa, Il-1b, Il-6, and Ccl2. M2 macrophages display
the upregulation of scavenger, mannose (CD206) and galactose
(Mgl-1) receptors, arginase 1 (Arg-1), which antagonizes iNOS
activity, and Il-10 as well as the upregulation of other genes
such as chitinases Ym1 and Ym2 and resistin-like molecule
(Relm) a (also known as FIZZ) (Mosser and Edwards, 2008).
Notably, Alox15 is an IL-4- and 1L-13-responsive gene, and
recent transcriptomics analyses have demonstrated that
Alox15 is highly upregulated in macrophages isolated during
the resolution of acute inflammation (Stables et al., 2011). Along
these lines, Th2-skewed human peripheral blood monocytes ex-
press high levels of Alox15 and produce PD1 from endogenous
DHA (Ariel et al., 2005). Moreover, M2 macrophages produce
elevated SPM levels, including MaR1, PD1, and RvD5 in com-
parison to M1 polarized macrophages in vitro, as assessed
with metabolipidomic analysis (Dalli and Serhan, 2012).
In line with SPM protective actions against adipose tissue
inflammation and in addition to their increased biosynthesis by
M2 macrophages, SPMs skew adipose tissue macrophages
toward an M2 phenotype. RvD1 upregulates a panel of M2
markers that includes Il-10, CD206, Relm-a, and Ym1 in macro-
phages from obese adipose tissue (Figure 4) (Titos et al., 2011).
RvD1 also remarkably stimulates Arg-1 expression while
promoting nonphlogistic macrophage phagocytosis and attenu-
ating IFNg- and LPS-induced Th1 cytokine secretion (Titos et al.,
2011). Similar findings have been reported on the ability of RvD1
to improve insulin sensitivity by increasing the percentage of
macrophages expressing the M2 marker Mgl-1 in adipose
tissue from obese diabetic mice (Hellmann et al., 2011). The
ability of SPMs to modify macrophage plasticity has also
been demonstrated by Schif-Zuck et al. (2011). The administra-
tion of RvD1 or RvE1 to mice enhances appearance of CD11blow
macrophages during acute peritonitis by reducing the
number of engulfment-related events required for macrophage
Figure 4. Biosynthesis and Biological Role of SPMs in Adipose Tissue
In the adipose tissue, the major long-chain polyunsaturated fatty acids, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid are endogenously
converted into potent anti-inflammatory and proresolving SPM lipoxin A4, resolvin E1, protectin D1, and resolvin D1. In inflamed adipose tissue, these mediators
evoke cell-specific regulatory actions on adipokine expression and/or secretion by adipocytes and macrophages. Resolvin D1 also promotes macrophage
polarization toward the anti-inflammatoryM2 phenotype. A section of adipose tissue immunostainedwith an F4/80 antibody, depicting a remarkable infiltration of
macrophages forming ‘‘crown-like’’ structures within surrounding adipocytes, is shown in the upper right corner. COX-2, cyclooxygenase-2; Cyt P450, cyto-
chrome P450; LOX, lipoxygenase; IL, interleukin; TNFa, tumor necrosis factor a; MCP-1, monocyte chemoattractant protein-1.
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phages to produce proinflammatory cytokines upon LPS
stimulation. Altogether, the ability of SPMs to modulate the plas-
ticity of tissue macrophages offers new opportunities for facili-
tating the resolution of adipose tissue inflammation in metabolic
diseases.
Steatohepatitis: Failed Resolution of Metabolic Liver
Disease?
Nonalcoholic fatty liver disease (NAFLD) is a condition ranging
from steatosis or simple accumulation of triglycerides in the
cytoplasm of hepatocytes to steatosis combined with inflamma-
tion (steatohepatitis or NASH) in the absence of excessive
alcohol consumption (Day, 2011). NAFLD is considered to be
the hepatic manifestation of the metabolic syndrome, given their
prevalence is coincidental in western society (Day, 2011). The
strong association between NAFLD and obesity has been well
documented in the European DIONYSOS study cohort (3,000
participants), in whichNAFLDwas present in 25%of participants
with a normal weight (body mass index [BMI] 20.0–24.9 kg/m2),
67% of overweight participants (BMI 25.0–29.9 kg/m2), and 94%
of participants with obesity (BMI 30 kg/m2) (Bedogni et al.,
2005). Although hepatic steatosis is generally an asymptomatic
premorbid condition, it increases the vulnerability of the liver toprogress to more advanced and irreversible forms of liver dis-
ease (Day, 2011). Steatotic livers are indeed more susceptible
to tissue-damaging effects of oxidative stress and inflammatory
mediators, which pave the way for progressive liver damage into
NASH, fibrosis, and, ultimately, cirrhosis (Day, 2011). In addition
to increased FFA release and exacerbated production of proin-
flammatory adipokines by adipose tissue (Tilg and Moschen,
2008; Gregor and Hotamisligil, 2011), hepatic insulin resistance
and hepatic steatosis in obesity are also driven by the activation
of classical inflammatory lipid-mediator pathways. This view is
consistent with earlier observations reporting that omega-6-
derived eicosanoids, especially LTB4, play a role in the progres-
sion of metabolic diseases. Indeed, leukotrienes would promote
hyperlipidemia-dependent vascular complications and repre-
sent a risk factor in atherosclerosis (Zhao et al., 2004). Given
that the sequence of molecular and cellular events underlying
atherosclerosis (i.e., lipid accumulation, mounting inflammation,
and progression to fibrous plaque in the arterial vessel wall) is
fundamentally similar to that described for NAFLD, it was not
surprising that leukotrienes also contribute to metabolic liver
disease. Indeed, the 5-LOX pathway is markedly activated in pa-
tients and animals with NAFLD (Puri et al., 2009; Horrillo et al.,
2010). Consistently, either pharmacological or genetic inhibition
of the leukotriene pathway protects against HFD-inducedCell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc. 31
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hepatocyte cell death (Horrillo et al., 2010; Martı´nez-Clemente
et al., 2010; Spite et al., 2011).
Omega-3 fatty acid precursors and SPMs exert opposite roles
in hepatic steatosis to those described for omega-6-derived
eicosanoids. In this regard, the administration of an omega-3-
enriched diet for 5 weeks significantly alleviates hepatic steato-
sis in ob/ob mice, an experimental model of obesity-induced
insulin resistance and fatty liver disease (Gonza´lez-Pe´riz et al.,
2009). This antisteatotic effect is associated with improved
insulin tolerance and changes in the expression of specific
adipocyte-derived factors (i.e., adipokines) that orchestrate the
interaction between adipose tissue and the liver (Gonza´lez-Pe´riz
et al., 2009). In parallel with this antisteatotic effect, omega-3-
enriched diets also ameliorate inflammatory liver injury in mice
(Gonza´lez-Pe´riz et al., 2006). The hepatoprotective actions of
omega-3 diets are associated with the increased generation of
SPMs in liver tissue (i.e., PD1 and 17S-HDHA). These SPMs
are able to attenuate DNA damage and oxidative stress in hepa-
tocytes and reduce TNFa release in macrophages (Gonza´lez-
Pe´riz et al., 2006). A proof of concept of the beneficial role of
omega-3 fatty acids in metabolic liver disease has recently
been gathered in mice with the transgenic expression of the
C. elegans fat-1 gene, which encodes an omega-3 desaturase
capable of generating omega-3 fatty acids from the omega-6
type (see above) (Lo´pez-Vicario et al., 2013). These fat-1 mice
have a more balanced omega-6/omega-3 ratio and are pro-
tected from obesity-induced hepatic insulin resistance, steatosis
and inflammation. Interestingly, transgenic fat-1 mice show
increased formation of resolvins (Hudert et al., 2006). Consis-
tently, we reproduce the protective actions of omega-3 fatty
acids against inflammatory injury observed in fat-1 hepatocytes
by incubating wild-type hepatocytes with nanomolar concentra-
tions of RvD1 (Lo´pez-Vicario et al., 2013). Little information is
available on the role of other SPMs (i.e., lipoxins and maresins)
in metabolic liver disease, although the liver is a rich source of
LXA4 and 15-epi-LXA4 (Titos et al., 1999), the formation of which
attenuates IL-8 secretion by hepatocytes (Planaguma` et al.,
2002).
Concluding Remarks
Although partial gastrectomy and other types of bariatric sur-
gery are successful in weight loss (Carlin et al., 2013), new
approaches are needed. Recent efforts have uncovered
extensive interactions between immunity and metabolism and
have led to the identification of salient mechanisms under-
lying the initiation of inflammatory signaling in the context of
metabolic diseases. Less is known about the resolution of
inflammation or SPM biosynthesis in the context of metabolic
diseases. As discussed in the present review, some of the
features of active resolution appear to be deficient in meta-
bolic disease, and treatment with specific SPMs improves
metabolism and immunity. Nevertheless, several key questions
remain. Is resolution impaired in states of nutrient excess or
insulin resistance? How do the proresolving mediators impact
intermediary metabolism, and how are these mediators, in
turn, affected by insulin resistance? How do metabolic dis-
eases perturb lipid mediator class switching? Is this merely a
problem of substrate ratios in the diet and utilization (e.g., AA32 Cell Metabolism 19, January 7, 2014 ª2014 Elsevier Inc.versus EPA and DHA), or are there unappreciated changes
in the expression or regulation of the enzymes involved in
SPM biosynthesis? How does nutrient metabolism regulate
SPM biosynthesis at the molecular level within adipose tis-
sues? Given that SPM circuits are active in adipose tissue
and are decreased in obesity (Cla`ria et al., 2013), what are
the roles of specific SPMs in lean noninflamed adipose tissue
homeostasis?
Mapping of lipid mediator networks during the resolution of
inflammation has increased our understanding of the process
of resolution itself and has informed new therapeutic strategies
for treating inflammation. Although animal studies show that
dietary intake of omega-3 fatty acids reduces inflammation
while, at the same time, improving systemic metabolism and
increasing SPM biosynthesis, human studies have, in some
cases, failed to consistently demonstrate a beneficial effect of
omega-3 fatty acids on systemic metabolism (De Caterina,
2011). This discrepancy highlights the need for a more thor-
ough understanding of the impact of nutrient excess on local
SPM biosynthesis and SPM levels. It also raises the possibility
that the use of SPMs might represent a more targeted thera-
peutic approach than simply increasing omega-3 fatty acids
in the diet (Tabas and Glass, 2013). These fatty acids are pre-
cursors of lipid mediators that are several orders of magnitude
more potent and display stereospecific biological roles in
regulating inflammation (Serhan and Petasis, 2011; Serhan
and Chiang, 2013). Moreover, the anti-inflammatory effects of
omega-3 fatty acids are clearly regulated at multiple levels
(e.g., receptors and enzymatic activities), which might be inde-
pendently affected by disease. Hence, direct treatment with
lipid mediators, rather than the parent omega-3-fatty acids,
may be more effective in targeting inflammatory responses.
The notion that nonselective or off-target effects of omega-3
fatty acids might be problematic is supported by results sug-
gesting that, although a high intake of omega-3 fatty acids is
beneficial in some contexts, it can increase the appearance
of auto-oxidation products and may also increase the risk of
certain types of cancer (Brasky et al., 2013), or it is possible
that these disease populations are at risk because they are
unable to produce SPMs.
In resolution, all SPMs have two main functions: they stop
and limit further PMN entry and stimulate macrophage intake
and the clearance of apoptotic cells, debris, and bacteria; hence,
additional research is needed to identify how different SPMs
are biosynthesized in response to inflammatory challenges
within adipose tissues and how individual SPMs differ in their
individual actions. Therefore, it will be interesting to determine
whether different SPMs regulate distinct events in chronic
inflammation and to identify how individual SPMs differ in their
ability to regulate discrete processes in tissue-specific resolution
program(s) and tissue regeneration. In summation, it should
be pointed out that certain therapeutic strategies impact resolu-
tion, either positively (e.g., carbon monoxide and cyclin-depen-
dent kinase inhibitors) or negatively (e.g., selective COX-2 and
LOX inhibitors) (Chiang et al., 2013), and, thus, determining
how the resolution of inflammation in obesity is impacted may
be an essential criterion in developing future therapeutic
interventions aimed at combating inappropriate inflammation in
metabolic disease.
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